Latest News

Senhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination

May

05

2026

Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development

Apr

14

2026

Breakthrough at 2026 AACR! Senhwa Biosciences’ CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy

Mar

17

2026

Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape the Global Immunotherapy Landscape

Mar

03

2026

Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC “Blockbuster” Therapy

Dec

29

2025

Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference

Dec

23

2025

Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors-BeOne

Dec

11

2025

Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy

Oct

16

2025